4.6 Article

Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry

Journal

THORAX
Volume 67, Issue 8, Pages 754-756

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/thoraxjnl-2012-201869

Keywords

-

Funding

  1. Astra Zeneca
  2. GlaxoSmithKline
  3. Novartis
  4. Medimmune
  5. HSC RD (NI)
  6. Wellcome Senior Clinical Fellowship
  7. AZ
  8. Amgen
  9. Chiesi, BI
  10. Roche
  11. Genentech
  12. Merck Sharpe Dohme
  13. Nycomed
  14. Medical Research Council [G1000758B, G1000758] Funding Source: researchfish

Ask authors/readers for more resources

Refractory asthma represents a significant unmet clinical need. Data from a national online registry audited clinical outcome in 349 adults with refractory asthma from four UK specialist centres in the British Thoracic Society Difficult Asthma Network. At follow-up, lung function improved, with a reduction in important healthcare outcomes, specifically hospital admission, unscheduled healthcare visits and rescue courses of oral steroids. The most frequent therapeutic intervention was maintenance oral corticosteroids and most steroid sparing agents (apart from omalizumab) demonstrated minimal steroid sparing benefit. A significant unmet clinical need remains in this group, specifically a requirement for therapies which reduce systemic steroid exposure.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available